13 September 2022 : Original article
Diagnostic Role of Tumor Markers for Hepatocellular Carcinoma in Liver Transplantation Candidates: An Analysis Using the Korean Organ Transplantation Registry Database
Woo-Hyoung Kang
1ABCDE, Shin Hwang1ABCDEFG*, Jong Man Kim 2BCE, Kwang-Woong Lee3BDE, Dong Jin Joo4BDE, Young Kyoung You5BDE, Je Ho Ryu6BCE, Bong-Wan Kim7BDE, Donglak Choi8BDE, Dong-Sik Kim 9BDE, Yang Won Nah10BDE
DOI: 10.12659/AOT.936937
Ann Transplant 2022; 27:e936937
Table 2 Comparison of diagnostic predictability of tumor markers for hepatocellular carcinoma.
| Group | AFP >7.5 ng/mL | PIVKA-II >40 mAU/mL | ||
|---|---|---|---|---|
| Sensitivity | Specificity | Sensitivity | Specificity | |
| All | 44.9% | 79.7% | 62.6% | 46.9% |
| HBV | 44.4% | 70.6% | 32.9% | 73.6% |
| HCV | 58.0% | 89.3% | 49.5% | 64.3% |
| ALD | 36.1% | 86.2% | 42.1% | 62.3% |
| Other | 47.8% | 74.3% | 42.0% | 62.2% |
| AFP – alpha-fetoprotein; PIVKA-II – protein induced by vitamin K absence or antagonist-II; HBV – hepatitis B virus; HCV – hepatitis C virus; ALD – alcoholic liver disease. | ||||